Investor Tej Kohli Expands ‘Venture Philanthropy’ Into 3d-printed Bionic Arms
29.11.2019 10:00:00 EET | Business Wire | Press release
Investor Tej Kohli is to fund the purchase of ten bionic arms for children with limb differences in the UK. The Tej Kohli Foundation hopes that its commitment to fund arms for ten children over the next 5 months as part of its ‘Future Bionics’ program will highlight how assistive technology can substantially improve the lives and confidence of young people living with disabilities. The Tej Kohli Foundation hopes to inspire and influence other healthcare institutions to follow this lead and discover the advanced 3D-printed technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005558/en/
Tej Kohli Foundation co-Founder Wendy Kohli, Tilly Lockey wearing Open Bionics arms, Tej Kohli Foundation co-Founder Tej Kohli, future Hero Arm recipient Jacob Pickering, future Hero Arm recipient Harris Gribble (Photo: Business Wire)
In England the National Health Service (‘NHS’) currently provides a single-grip myoelectric-controlled (‘myo’) prosthesis at a cost of approximately £8,000. However, the Open Bionics Hero Arm can be controlled with the electrical signals generated by a user’s muscles and has superior multi-grip functionality that enables users to perform many more everyday activities.
The Open Bionics Hero Arm costs £10,000 through a private prosthetics clinic in the UK, whereas other advanced multi-grip bionic hands cost £30,000 - £60,000. The Tej Kohli Foundation will spend an initial £100,000 to launch its ‘Future Bionics’ programme, which will enable ten British children to access not just a superior technology, but a better life.
The first Hero Arm recipient is 10-year-old Jacob Pickering from Blackburn, who will receive his new Hero Arm just in time for Christmas. Jacob was born without his right arm as a result of amniotic band syndrome. All Jacob has spoken about for the past month is the Hero Arm, and his father David is “completely overwhelmed” that Jacob has been selected for a donation and claims that it will “change Jacob’s life”. The second Hero Arm recipient is 14-year-old Harris Gribble from Exeter, who is a keen Rugby and Cricket player.
The lightweight Hero Arm is currently the only multi-grip myo prosthetic arm that is available for paediatric use. The enhanced ability of the user to be able to personalise their 3D-printed Open Bionics Hero Arm is also a huge boost to mental well-being and to perceived social acceptance. This is particularly important for younger people.
Investor Tej Kohli first discovered Bristol-based Open Bionics when he invested into ‘Rewired’, a robotics-focused venture studio ‘with a humanitarian bent’ that was a very-early backer of Open Bionics in 2017.
Tej Kohli, Co-Founder of the Tej Kohli Foundation said:
“We started the Tej Kohli Foundation in 2005 with a project to provide daily meals for 1,000 children in Costa Rica. Since then the Tej Kohli Foundation has supported projects all over the world and helped tens of thousands of people, especially those living with disability. This gift of ten bionic arms is the first project that we have ever initiated in the UK. I see it as just the beginning, and my hope is that this gift will help to highlight the positive difference that technology can make to the confidence and prospects of a younger person. We’re doing this as an example, but we hope that others will follow our lead. These technologies are now so accessible and affordable that healthcare organisations such as the NHS should do more to embrace and improve access to them for disabled young people.”
Samantha Payne, Co-Founder and COO of Open Bionics said:
“We’re really grateful to the Tej Kohli Foundation for pledging to fund advanced bionic arms for ten children in the UK. These children are amongst dozens of people with upper limb differences in the UK fundraising right now for a Hero Arm. We've worked really hard to achieve a price point for the device that is acceptable for existing NHS budgets for prosthetic provision, and we very much hope the NHS sees how helpful these devices are and will begin offering them to the people who need them.”
Children and adults with below-elbow limb differences can register their interest at www.openbionics.com.
Images and profiles of the recipients of the Hero Arms can be downloaded here: https://www.dropbox.com/sh/wakjc66nz1ljjpb/AADwtFqgu7j-xhEtTRzYuBdsa?dl=0
About Open Bionics
Open Bionics was founded in 2014 by Joel Gibbard and Samantha Payne with the goal of developing affordable, assistive devices that enhance the human body. In other words, Open Bionics turns disabilities into superpowers. The Bristol-based bionics company is known globally for using 3D printing and 3D scanning, along with some clever software and design, to make advanced, affordable and accessible bionic limbs. In May 2018, the company released the Hero Arm, the world’s first medically approved 3D-printed bionic arm, and the very first multi-grip bionic arm for children as young as eight years old. The Hero Arm is available now through private prosthetic clinics all around the world. Open Bionics have a development contract with NHS England, with the aim of offering the Hero Arm on the NHS in the UK. They also have royalty-free licensing agreements with Disney, Marvel, Lucasfilm, Eidos Montreal and Twentieth Century Fox, making science fiction a reality.
About the Tej Kohli Foundation
Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness, which disproportionately impacts young people in poorer countries. Since 2015 the Foundation has funded free corneal transplants in poor communities in India; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness.
Through its ‘Impact Initiatives’ the Tej Kohli Foundation also makes direct interventions into the lives of young people whose confidence and prospects can be substantially improved. Previous ‘Impact Initiatives’ have included financial support for disabled children in Costa Rice, feeding schoolchildren at after-school clubs in poor communities, and also producing a short film to highlight the plight of young people in India living with a rare genetic disease.
http://www.tejkohlifoundation.com
About Tej Kohli
Tej Kohli is a London-based investor and philanthropist who first rose to success selling technology solutions and payments software during the dot com boom. His current focus is as a real estate investor within the world’s newly emerging technology hubs, and as a backer of high-impact AI, robotics and genomics ventures that have the potential to transform lives and change the world. He is also a major esports investor.
Tej Kohli is a distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.
END
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191128005558/en/
Contact information
To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff
(Buchanan Communications)
kohliventures@buchanan.uk.com
+44 207 466 5000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings & Gatbits IT Infrastructure Announce Launch of GTBS Digital Ecosystem; Mainnet Set for April 202630.3.2026 21:30:00 EEST | Press release
The Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings, in collaboration with Gatbits IT Infrastructure, has officially announced the launch of the GTBS Digital Ecosystem, marking a significant step forward in the global Web3 space. The announcement follows the successful launch of the native GTBS Coin on December 25, with the ecosystem’s mainnet scheduled to go live in April 2026. GTBS represents a full-stack Web3 ecosystem integrating blockchain, artificial intelligence, decentralized finance (DeFi), entertainment, gaming, media, and cloud infrastructure into a unified platform. Built on the philosophy of “All Commitment On Time,” the ecosystem focuses on delivering reliability, scalability, and real-world utility. Designed as a comprehensive digital infrastructure, GTBS goes beyond standalone crypto platforms by offering an integrated environment for users, developers, creators, and enterprises. Its proprietary Layer-1 blockchain powers seamless interaction across se
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
